Small-cap biotech stocks can be attractive long-term investments, but they also carry significant risks.
Biotech companies, particularly those with market capitalizations of less than $2 billion, frequently trade at low valuations compared to their future potential. A successful drug approval or positive clinical trial outcome can send a stock skyrocketing.
